Option Care Health Inc

Option Care Health Inc

  • Price (EUR)3.86
  • Today's Change0.06 / 1.58%
  • Shares traded0.00
  • 1 Year change17.33%
  • Beta0.4477
Data delayed at least 15 minutes, as of Jan 24 2020 14:34 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Option Care Health, Inc., formerly BioScrip, Inc., incorporated on March 22, 1996, provides home and alternate site infusion services in the United States. The Company provides a range of infusion therapies to patients. It provides care for patients with acute and chronic conditions. Its therapeutic services include anti-infective, Option Care Women’s health, bleeding disorders, heart failure, immunoglobulin, nutrition support, chronic inflammatory disorders and specialized therapies. Its other services include hemophilia care, transplant and pediatrics.

  • Revenue in USD (TTM)1.77bn
  • Net income in USD-78.43m
  • Incorporated1996
  • Employees1.66k
  • Location
    Option Care Health Inc3000 Lakeside Dr Ste 300NBANNOCKBURN 60015-5405United StatesUSA
  • Phone+1 (312) 940-2443
  • Fax+1 (800) 253-5177
  • Websitehttps://www.bioscrip.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BIOS:NAQ since
Option Care Enterprises IncDeal completed15 Mar 201915 Mar 2019Deal completed22.49%2.82bn
Data delayed at least 15 minutes, as of Jan 24 2020 17:16 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.